AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16174986 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic sinus surgery (ESS) for chronic sinusitis in patients without asthma
Number of subjects: 88
Study 12854267 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium ascorbate (1 gram daily for 14 +/- 3 days)
Number of subjects: 133
Study 12854267 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identically looking tablets)
Number of subjects: 133
Study 10535703 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% oxygen
Number of subjects: 29
Study 10535703 — intervention group
Group type: COMPARATOR
Intervention: Medical air (control)
Number of subjects: 29
Study 8561070 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 polyunsaturated fatty acid‐rich fish oil supplement for 21 days
Number of subjects: 12
Study 8561070 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 polyunsaturated fatty acid‐rich fish oil supplement with interferon‐gamma incubation
Number of subjects: 12
Study 8561070 — intervention group
Group type: COMPARATOR
Intervention: No supplement (control group)
Number of subjects: 12
Study 1907839 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin with propranolol (40 mg twice daily)
Number of subjects: 16
Study 1907839 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin with propranolol (40 mg twice daily)
Number of subjects: 16
Study 1907839 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin
Number of subjects: 16
Study 1907839 — intervention group
Group type: COMPARATOR
Intervention: Lovastatin
Number of subjects: 16
Study 6125188 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 19
Study 6125188 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 19
Study 6125188 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 19
Study 6125188 — intervention group
Group type: COMPARATOR
Intervention: Atenolol and Propranolol
Number of subjects: 19
Study 6125188 — intervention group
Group type: COMPARATOR
Intervention: Atenolol, Propranolol, and Pindolol
Number of subjects: 19
Study 29462231 — intervention group
Group type: EXPERIMENTAL
Intervention: apremilast 30 mg twice daily
Number of subjects: 136
Study 29462231 — intervention group
Group type: COMPARATOR
Intervention: placebo (switched to apremilast after 16 weeks)
Number of subjects: 136
Study 28077530 — intervention group
Group type: EXPERIMENTAL
Intervention: Maize-derived HES solution
Number of subjects: 118
Study 28077530 — intervention group
Group type: COMPARATOR
Intervention: Potato-derived HES solution
Number of subjects: 118
Study 24548148 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to preferred music during flexible cystoscopy
Number of subjects: 124
Study 24548148 — intervention group
Group type: COMPARATOR
Intervention: Control group (unable to listen to music)
Number of subjects: 124
Study 22903145 — intervention group
Group type: EXPERIMENTAL
Intervention: Action Planning (AP) program
Number of subjects: 2031
Study 22903145 — intervention group
Group type: EXPERIMENTAL
Intervention: Action Planning plus (AP+) program
Number of subjects: 2031
Study 22903145 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2031
Study 20694935 — intervention group
Group type: EXPERIMENTAL
Intervention: Elite race car drivers
Number of subjects: 26
Study 20694935 — intervention group
Group type: COMPARATOR
Intervention: Physically active controls
Number of subjects: 26
Study 19008724 — intervention group
Group type: EXPERIMENTAL
Intervention: moxonidine (0.3 mg twice daily)
Number of subjects: 87
Study 19008724 — intervention group
Group type: COMPARATOR
Intervention: atenolol (50 mg once daily)
Number of subjects: 87
Study 15705324 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycobacterium haemophilum-specific PCR
Number of subjects: 89
Study 15705324 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time PCR
Number of subjects: 89
Study 15705324 — intervention group
Group type: COMPARATOR
Intervention: Culture
Number of subjects: 89
Study 15705324 — intervention group
Group type: EXPERIMENTAL
Intervention: M. avium detection
Number of subjects: 89
Study 14571069 — intervention group
Group type: EXPERIMENTAL
Intervention: Moisturizing cream applied twice daily for 6 weeks
Number of subjects: 16
Study 14571069 — intervention group
Group type: COMPARATOR
Intervention: Non-treated control side
Number of subjects: 16
Study 10799371 — intervention group
Group type: COMPARATOR
Intervention: Black tea
Number of subjects: 20
Study 10799371 — intervention group
Group type: COMPARATOR
Intervention: Green tea
Number of subjects: 20
Study 10799371 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 20
Study 10799371 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary 4-O-methylgallic acid
Number of subjects: 20
Study 8637438 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glycemic-index diet (LGI)
Number of subjects: 32
Study 8637438 — intervention group
Group type: COMPARATOR
Intervention: High-glycemic-index diet (HGI)
Number of subjects: 32
Study 1360558 — intervention group
Group type: EXPERIMENTAL
Intervention: Active negative pressure ventilation (NPV)
Number of subjects: 184
Study 1360558 — intervention group
Group type: COMPARATOR
Intervention: Sham negative pressure ventilation (NPV)
Number of subjects: 184
Study 3909132 — intervention group
Group type: EXPERIMENTAL
Intervention: i.m. meptazinol (50, 100, 200mg)
Number of subjects: 128
Study 3909132 — intervention group
Group type: COMPARATOR
Intervention: i.m. morphine (4, 8 and 16 mg)
Number of subjects: 128
Study 30834812 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral hybrid therapy (UHT; unilateral robot‐assisted therapy + modified constraint‐induced movement therapy)
Number of subjects: 30
Study 30834812 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral hybrid therapy (BHT; bilateral robot‐assisted therapy + bilateral arm training)
Number of subjects: 30
Study 30834812 — intervention group
Group type: COMPARATOR
Intervention: Robot therapy (RT)
Number of subjects: 30
Study 29423521 — intervention group
Group type: EXPERIMENTAL
Intervention: Sym004, 12 mg/kg/wk (arm A)
Number of subjects: 254
Study 29423521 — intervention group
Group type: EXPERIMENTAL
Intervention: Sym004, 9 mg/kg loading dose followed by 6 mg/kg/wk (arm B)
Number of subjects: 254
Study 29423521 — intervention group
Group type: COMPARATOR
Intervention: Investigator's choice of treatment (arm C)
Number of subjects: 254
Study 26813548 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blocker (BB) treatment (any molecule and any dose)
Number of subjects: 2622
Study 26813548 — intervention group
Group type: COMPARATOR
Intervention: Non-BB treatment
Number of subjects: 2622
Study 25100236 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin (5 or 2.5 mg/day)
Number of subjects: 143
Study 25100236 — intervention group
Group type: COMPARATOR
Intervention: non-statin group
Number of subjects: 143
Study 22883585 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin gelatin sponge stickers
Number of subjects: 79
Study 22883585 — intervention group
Group type: COMPARATOR
Intervention: Conservative traditional drying method
Number of subjects: 79
Study 21059972 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-a-week supervised aerobic and resistance training plus structured exercise counseling
Number of subjects: 606
Study 21059972 — intervention group
Group type: COMPARATOR
Intervention: Counseling alone (control group)
Number of subjects: 606
Study 17561440 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 53
Study 17561440 — intervention group
Group type: COMPARATOR
Intervention: Carvedilol
Number of subjects: 53
Study 15769489 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with Parkinson's disease (PD)
Number of subjects: 32
Study 15769489 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 32
Study 10855156 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal case management by professional nurses
Number of subjects: 0
Study 9095400 — intervention group
Group type: EXPERIMENTAL
Intervention: Remacemide hydrochloride 300 mg twice daily
Number of subjects: 11
Study 9095400 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 9095400 — intervention group
Group type: EXPERIMENTAL
Intervention: Remacemide hydrochloride
Number of subjects: 11
Study 8466688 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapse Prevention (RP)
Number of subjects: 95
Study 8466688 — intervention group
Group type: COMPARATOR
Intervention: Brief Intervention (BI)
Number of subjects: 95
Study 8466688 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 95
Study 3514124 — intervention group
Group type: EXPERIMENTAL
Intervention: Open two‐bottle systems
Number of subjects: 43
Study 3514124 — intervention group
Group type: COMPARATOR
Intervention: Closed systems
Number of subjects: 43
Study 3514124 — intervention group
Group type: EXPERIMENTAL
Intervention: Open system
Number of subjects: 43
Study 3514124 — intervention group
Group type: COMPARATOR
Intervention: Closed system
Number of subjects: 43
Study 29933562 — intervention group
Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA 500U
Number of subjects: 42
Study 29933562 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 27680049 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy
Number of subjects: 32
Study 27680049 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy associated with Essential Fatty Acids
Number of subjects: 32
Study 27680049 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 32
Study 23803884 — intervention group
Group type: EXPERIMENTAL
Intervention: LCPUFA supplementation (0.32%, 0.64%, and 0.96% of total fatty acids, with ARA at 0.64%)
Number of subjects: 81
Study 23803884 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no LCPUFA supplementation)
Number of subjects: 81
Study 20189659 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal tube cuff lidocaine (2% lidocaine)
Number of subjects: 176
Study 20189659 — intervention group
Group type: COMPARATOR
Intervention: Intravenous lidocaine (1.5mg/kg of 2% lidocaine)
Number of subjects: 176
Study 20189659 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal tube cuff saline
Number of subjects: 176
Study 20189659 — intervention group
Group type: COMPARATOR
Intervention: Intravenous saline
Number of subjects: 176
Study 18925883 — intervention group
Group type: EXPERIMENTAL
Intervention: Varicella immunization (0.7% immunized)
Number of subjects: 2184
Study 18925883 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertussis immunization (1.7% nonimmunized)
Number of subjects: 2184
Study 18925883 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative received vaccine doses
Number of subjects: 2184
Study 18925883 — intervention group
Group type: COMPARATOR
Intervention: Common childhood immunization in the first year
Number of subjects: 2184
Study 16687966 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with amlodipine besylate/benazepril hydrochloride 5/20 mg
Number of subjects: 505
Study 16687966 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine besylate 5 mg
Number of subjects: 505
Study 16687966 — intervention group
Group type: COMPARATOR
Intervention: Benazepril hydrochloride 20 mg
Number of subjects: 505
Study 14660988 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based intervention to general practitioners incorporating multidisciplinary telephone case conferencing
Number of subjects: 1455
Study 14660988 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 1455
Study 11075844 — intervention group
Group type: EXPERIMENTAL
Intervention: Almotriptan 6.25 mg
Number of subjects: 1013
Study 11075844 — intervention group
Group type: EXPERIMENTAL
Intervention: Almotriptan 12.5 mg
Number of subjects: 1013
Study 11075844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1013
Study 11075844 — intervention group
Group type: EXPERIMENTAL
Intervention: Almotriptan (both doses)
Number of subjects: 1013
Study 9364179 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective gloves
Number of subjects: 0
Study 9364179 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective covers for the lower arm
Number of subjects: 0
Study 9364179 — intervention group
Group type: COMPARATOR
Intervention: Hospitalisation rate for hand and lower arm injuries
Number of subjects: 0
Study 1411094 — intervention group
Group type: EXPERIMENTAL
Intervention: Puppet shadow play (wayang) incorporating the arthritis community education (ACE)
Number of subjects: 1105
Study 1411094 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched for age, sex, and educational level who did not see the play)
Number of subjects: 1105
Study 3490176 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol (4 micrograms/kg intravenously on entry and on the second and third study days)
Number of subjects: 24
Study 3490176 — intervention group
Group type: COMPARATOR
Intervention: Control (no calcitriol)
Number of subjects: 24
Study 3490176 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol
Number of subjects: 24
Study 28993261 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-FODMAP diet (n = 46)
Number of subjects: 93
Study 28993261 — intervention group
Group type: COMPARATOR
Intervention: Sham diet (n = 47)
Number of subjects: 93
Study 28993261 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic (n = 49)
Number of subjects: 93
Study 28993261 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 44)
Number of subjects: 93
Study 27735851 — intervention group
Group type: EXPERIMENTAL
Intervention: Explaining the effectiveness of precautions
Number of subjects: 1717
Study 27735851 — intervention group
Group type: EXPERIMENTAL
Intervention: Amending precautionary messages for consistency
Number of subjects: 1717
Study 27735851 — intervention group
Group type: EXPERIMENTAL
Intervention: Original precautionary messages
Number of subjects: 1717
Study 24438094 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild COPD patients
Number of subjects: 37
Study 24438094 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 37
Study 22722501 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone ER (6-9 mg/d)
Number of subjects: 459
Study 22722501 — intervention group
Group type: COMPARATOR
Intervention: Oral Olanzapine (10-15 mg/d)
Number of subjects: 459
Study 20512586 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression Stockings (CS) during exercise and recovery
Number of subjects: 8
Study 20512586 — intervention group
Group type: COMPARATOR
Intervention: No Compression Stockings (no CS) during exercise and recovery
Number of subjects: 8
Study 20512586 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression Stockings (CS) during recovery
Number of subjects: 8
Study 20512586 — intervention group
Group type: COMPARATOR
Intervention: No Compression Stockings (no CS) during recovery
Number of subjects: 8
Study 18824933 — intervention group
Group type: EXPERIMENTAL
Intervention: Sit-ups (SU) test
Number of subjects: 100
Study 18824933 — intervention group
Group type: EXPERIMENTAL
Intervention: Push-ups (PU) test
Number of subjects: 100
Study 18824933 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-validation of SU
Number of subjects: 100
Study 18824933 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-validation of PU
Number of subjects: 100
Study 18824933 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired-samples t-tests for SU
Number of subjects: 100
Study 18824933 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired-samples t-tests for PU
Number of subjects: 100
Study 19720897 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed-carboplatin (pemetrexed 500 mg/m² on day 1; carboplatin AUC 5 on day 1)
Number of subjects: 908
Study 19720897 — intervention group
Group type: COMPARATOR
Intervention: Etoposide-carboplatin (etoposide 100 mg/m² on days 1-3; carboplatin AUC 5 on day 1)
Number of subjects: 908
Study 19720897 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed-carboplatin
Number of subjects: 908
Study 15815206 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic-supplemented formula containing Bifidobacterium lactis and Streptococcus thermophilus (10 viable cells each) for 15 days.
Number of subjects: 80
Study 15815206 — intervention group
Group type: COMPARATOR
Intervention: Nonsupplemented formula for the entire duration (30 days).
Number of subjects: 80
Study 11919238 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy (chemotherapy, hormonal therapy, or both) for node-positive disease
Number of subjects: 8106
Study 11919238 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined multidrug chemotherapy plus tamoxifen for node-positive disease
Number of subjects: 8106
Study 11919238 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy for node-negative disease
Number of subjects: 8106
Study 11919238 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen for node-negative tumors > or = 1 cm diagnosed in 1995
Number of subjects: 8106
Study 11919238 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy for node-negative tumors > or = 1 cm diagnosed in 1995
Number of subjects: 8106
Study 11919238 — intervention group
Group type: EXPERIMENTAL
Intervention: Both tamoxifen and combination chemotherapy for node-negative tumors > or = 1 cm diagnosed in 1995
Number of subjects: 8106
Study 11919238 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen for node-negative tumors > or = 1 cm diagnosed in 1987
Number of subjects: 8106
Study 11919238 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy for node-negative tumors > or = 1 cm diagnosed in 1987
Number of subjects: 8106
Study 11919238 — intervention group
Group type: EXPERIMENTAL
Intervention: Both tamoxifen and combination chemotherapy for node-negative tumors > or = 1 cm diagnosed in 1987
Number of subjects: 8106
Study 9598218 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg of fenfluramine (FEN)
Number of subjects: 19
Study 9598218 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 8185343 — intervention group
Group type: EXPERIMENTAL
Intervention: FUT-187 (sepimostat mesilate) 300 mg/day
Number of subjects: 40
Study 8185343 — intervention group
Group type: EXPERIMENTAL
Intervention: FUT-187 (sepimostat mesilate) 400 mg/day
Number of subjects: 40
Study 2820312 — intervention group
Group type: EXPERIMENTAL
Intervention: Vindesine (3 mg/m2 X 3) plus cisplatin (80‐120 mg/m2)
Number of subjects: 36
Study 2820312 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin C (8 mg/m2) plus vindesine (2 mg/m2 X 3) plus cisplatin (80‐120 mg/m2)
Number of subjects: 36
Study 2820312 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin C, vindesine and cisplatin
Number of subjects: 36
Study 12947355 — intervention group
Group type: EXPERIMENTAL
Intervention: New therapy
Number of subjects: 0
Study 12947355 — intervention group
Group type: EXPERIMENTAL
Intervention: Equivalence and noninferiority designs
Number of subjects: 0
Study 12947355 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical differences between trial designs
Number of subjects: 0
Study 12947355 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed guideline for reporting
Number of subjects: 0
Study 30001547 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonological Reading and Writing Remediation Program (24 cumulative sessions, twice a week, 30 min each)
Number of subjects: 20
Study 30001547 — intervention group
Group type: COMPARATOR
Intervention: Control group (no remediation)
Number of subjects: 20
Study 27726426 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 101
Study 27726426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 24241491 — intervention group
Group type: EXPERIMENTAL
Intervention: sirolimus and tacrolimus
Number of subjects: 71
Study 24241491 — intervention group
Group type: COMPARATOR
Intervention: methotrexate and tacrolimus
Number of subjects: 71
Study 22495941 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram monotherapy (escitalopram and placebo)
Number of subjects: 665
Study 22495941 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant combination (venlafaxine-XR and mirtazapine or escitalopram and bupropion-SR)
Number of subjects: 665
Study 22495941 — intervention group
Group type: COMPARATOR
Intervention: MDD with concurrent SUD
Number of subjects: 665
Study 22495941 — intervention group
Group type: COMPARATOR
Intervention: MDD without concurrent SUD
Number of subjects: 665
Study 20403483 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin therapy
Number of subjects: 0
Study 18763686 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.454% stannous fluoride/sodium hexametaphosphate dentifrice (SnF2/SHMP)
Number of subjects: 21
Study 18763686 — intervention group
Group type: COMPARATOR
Intervention: 0.76% sodium monofluorophosphate/zinc citrate dentifrice (ZnCit/SMFP)
Number of subjects: 21
Study 15837246 — intervention group
Group type: EXPERIMENTAL
Intervention: TAXUS stent
Number of subjects: 1314
Study 12810991 — intervention group
Group type: EXPERIMENTAL
Intervention: Iontophoresis with alternating current (AC)
Number of subjects: 0
Study 12810991 — intervention group
Group type: EXPERIMENTAL
Intervention: Iontophoresis with alternating current (AC) combined with anticholinergic drugs
Number of subjects: 0
Study 10380089 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone (3 x 500 microg)
Number of subjects: 16
Study 10380089 — intervention group
Group type: COMPARATOR
Intervention: Systemic dexamethasone (0.5 mg/kg/day)
Number of subjects: 16
Study 7483814 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant staphylokinase (10 mg intravenous infusion over 30 min)
Number of subjects: 50
Study 7483814 — intervention group
Group type: COMPARATOR
Intervention: Recombinant tissue-type plasminogen activator
Number of subjects: 50
Study 1682544 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg orally per day for 10 days
Number of subjects: 24
Study 1682544 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg orally per day for 20 or 30 days
Number of subjects: 24
Study 1682544 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg orally per day
Number of subjects: 24
Study 1682544 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg orally per day for at least 20 days
Number of subjects: 24
Study 6109991 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosomatostatin (Pro-SS)
Number of subjects: 0